Global SCS market to hit $3.6B by 2027 — 10 notes

Written by Megan Wood | November 28, 2017 | Print  |

The global spinal cord stimulators market is set to grow at a 6.4 percent compound annual growth rate through 2027, according to a Future Market Insights report.

Here are 10 notes:


1. In 2017, the market was valued at $2 billion, and will likely reach $3.57 billion by 2027.


2. SCS stimulators present an alternative to opioids, but they don't posses a vast amount of evidence-based data support.


3. Rechargeable SCS stimulators will likely hit $2.53 billion by 2027.


4. Non-rechargeable SCS stimulators will grow at a 4.6 percent CAGR through 2027.


5. Failed back surgery syndrome represents the greatest application of SCS stimulators.


6. Complex regional pain syndrome is another top SCS stimulator application, with an expected 5.8 percent CAGR through 2027.


7. Hospitals will remain the dominant end-user of SCS stimulators, raking in $627.9 million in 2017.


8. Ambulatory surgery centers will see spiked SCS stimulator demand, with a 6.8 percent CAGR through 2027.


9. North America leads the global market, with anticipated sales of $3 billion by 2027. Western Europe follows, with a 6.1 percent CAGR through 2027. Eastern Europe and Japan will both grow at a 6 percent CAGR through 2027.


10. Boston Scientific Corp., Medtronic, St. Jude Medical, Nevro Corp., Nuvectra Corp., Stimwave and Saluda Medical are leading market players.


More articles on devices:
U.S. orthopedic trauma devices market to grow at 3.63% CAGR to 2021: 4 trends
Staying competitive in the ever-changing orthopedic implant industry – Anatomics VP Dr. Dean Carson explains how
Who is Mazor Robotics' biggest competitor in the spine market?

© Copyright ASC COMMUNICATIONS 2018. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months